JP2015507636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015507636A5 JP2015507636A5 JP2014550596A JP2014550596A JP2015507636A5 JP 2015507636 A5 JP2015507636 A5 JP 2015507636A5 JP 2014550596 A JP2014550596 A JP 2014550596A JP 2014550596 A JP2014550596 A JP 2014550596A JP 2015507636 A5 JP2015507636 A5 JP 2015507636A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkenylene
- alkylene
- alkynylene
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims 29
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000005275 alkylenearyl group Chemical group 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000002947 alkylene group Chemical group 0.000 claims 14
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims 14
- 125000004450 alkenylene group Chemical group 0.000 claims 12
- 125000004419 alkynylene group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- -1 alkylene R 10 Chemical compound 0.000 claims 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000007830 nerve conduction Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012900057 | 2012-01-06 | ||
| AU2012900057A AU2012900057A0 (en) | 2012-01-06 | Methods of treatment or prophylaxis | |
| PCT/AU2013/000003 WO2013102242A1 (en) | 2012-01-06 | 2013-01-04 | Heterocyclic compounds and methods for their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015507636A JP2015507636A (ja) | 2015-03-12 |
| JP2015507636A5 true JP2015507636A5 (https=) | 2016-01-28 |
| JP6232384B2 JP6232384B2 (ja) | 2017-11-15 |
Family
ID=48744930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550596A Active JP6232384B2 (ja) | 2012-01-06 | 2013-01-04 | 複素環式化合物およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9624243B2 (https=) |
| EP (1) | EP2800738B1 (https=) |
| JP (1) | JP6232384B2 (https=) |
| CN (1) | CN107011229B (https=) |
| AU (1) | AU2013202982C1 (https=) |
| CA (1) | CA2860577C (https=) |
| ES (1) | ES2802251T3 (https=) |
| NZ (1) | NZ626973A (https=) |
| PL (1) | PL2800738T3 (https=) |
| PT (1) | PT2800738T (https=) |
| WO (1) | WO2013102242A1 (https=) |
| ZA (1) | ZA201405253B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| ES2802251T3 (es) | 2012-01-06 | 2021-01-18 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| ES2798289T3 (es) | 2012-01-25 | 2020-12-10 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| ES2883155T3 (es) | 2013-07-08 | 2021-12-07 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| CN105085358A (zh) * | 2014-05-07 | 2015-11-25 | 中国医学科学院药物研究所 | 4-取代吡咯烷甲酰基硫代吗啉类dpp-iv抑制剂 |
| JP6667551B2 (ja) * | 2015-01-13 | 2020-03-18 | ノバルティス アーゲー | アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体 |
| US10308628B2 (en) | 2015-03-12 | 2019-06-04 | Novartis Ag | Heterocyclic compounds and methods for their use |
| US11369608B2 (en) | 2017-10-27 | 2022-06-28 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting AVIL expression |
| CN117645606A (zh) | 2018-03-23 | 2024-03-05 | 北京泰德制药股份有限公司 | 受体抑制剂、包含其的药物组合物及其用途 |
| EP3962485A4 (en) * | 2019-05-02 | 2022-12-28 | University Of Virginia Patent Foundation | SUBSTITUTED (PIPERIDINE-1-YL)ARYL ANALOGUES TO MODULATE AVILACTIVITY |
| AU2020388645B2 (en) * | 2019-11-21 | 2026-03-19 | University Of Utah Research Foundation | TRPV4 receptor ligands |
| WO2021165927A1 (en) * | 2020-02-21 | 2021-08-26 | Wockhardt Bio Ag | 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents |
| CN115894498A (zh) * | 2022-10-01 | 2023-04-04 | 海化生命(厦门)科技有限公司 | 一种潜在抗病毒药物中间体bl及其合成方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654034A (en) | 1969-04-21 | 1972-04-04 | Eastman Kodak Co | Apparatus for positioning strip ends in a splicing alignment |
| US3654304A (en) * | 1970-01-26 | 1972-04-04 | Robins Co Inc A H | Alkyl 1 1a 2 6b-tetrahydrocycloprop(b)indole 1-carboxylates and acids |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| WO1995009859A1 (en) * | 1993-10-07 | 1995-04-13 | The Du Pont Merck Pharmaceutical Company | Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring |
| NZ281431A (en) * | 1994-02-22 | 1997-09-22 | Merrell Pharma Inc | Alkylamide-substituted indole derivatives |
| JPH0892207A (ja) * | 1994-07-26 | 1996-04-09 | Sankyo Co Ltd | ピロリジン誘導体 |
| US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| JPH11508894A (ja) * | 1995-06-30 | 1999-08-03 | メルク エンド カンパニー インコーポレーテッド | Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法 |
| CN101284773A (zh) * | 2001-08-09 | 2008-10-15 | 小野药品工业株式会社 | 羧酸衍生物及以它为活性成分的药剂 |
| US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| AU2003259131A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| CN100497302C (zh) | 2002-09-05 | 2009-06-10 | 神经研究公司 | 二芳基脲衍生物和它们作为氯通道阻滞剂的用途 |
| AU2004289174B2 (en) | 2003-07-29 | 2011-05-19 | Signature R&D Holdings, Lcc | Amino acid prodrugs |
| WO2006066361A1 (en) | 2004-12-24 | 2006-06-29 | The University Of Queensland | Method of treatment or prophylaxis |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| WO2007053406A1 (en) * | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
| CA2866540A1 (en) | 2006-03-20 | 2007-09-27 | Spinifex Pharmaceuticals Pty Ltd. | Method of treatment or prophylaxis of inflammatory pain |
| EP2203057A4 (en) * | 2007-09-20 | 2010-09-29 | Univ Rochester | METHOD AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES |
| EA017842B1 (ru) * | 2008-03-04 | 2013-03-29 | Вернэлис (Р&Д) Лтд. | Производные азетидина и их применение |
| US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5756800B2 (ja) * | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| US20110152233A1 (en) * | 2009-12-18 | 2011-06-23 | Henner Knust | Pyrrolidine compounds |
| CN102812003B (zh) * | 2009-12-18 | 2015-01-21 | 欧洲筛选有限公司 | 吡咯烷羧酸衍生物、药物组合物以及在代谢紊乱中作为g-蛋白偶联受体43(gpr43)激动剂使用的方法 |
| NZ601383A (en) | 2010-01-19 | 2014-07-25 | Spinifex Pharm Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| ES2802251T3 (es) | 2012-01-06 | 2021-01-18 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| ES2798289T3 (es) | 2012-01-25 | 2020-12-10 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| PT2807171T (pt) | 2012-01-25 | 2020-11-03 | Novartis Ag | Compostos heterocíclicos e métodos para a sua utilização |
| ES2883155T3 (es) | 2013-07-08 | 2021-12-07 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
-
2013
- 2013-01-04 ES ES13733645T patent/ES2802251T3/es active Active
- 2013-01-04 JP JP2014550596A patent/JP6232384B2/ja active Active
- 2013-01-04 US US14/370,737 patent/US9624243B2/en active Active
- 2013-01-04 CA CA2860577A patent/CA2860577C/en active Active
- 2013-01-04 PT PT137336459T patent/PT2800738T/pt unknown
- 2013-01-04 NZ NZ626973A patent/NZ626973A/en unknown
- 2013-01-04 PL PL13733645T patent/PL2800738T3/pl unknown
- 2013-01-04 AU AU2013202982A patent/AU2013202982C1/en active Active
- 2013-01-04 WO PCT/AU2013/000003 patent/WO2013102242A1/en not_active Ceased
- 2013-01-04 EP EP13733645.9A patent/EP2800738B1/en active Active
- 2013-01-04 CN CN201610930815.9A patent/CN107011229B/zh active Active
-
2014
- 2014-07-17 ZA ZA2014/05253A patent/ZA201405253B/en unknown
-
2017
- 2017-02-06 US US15/425,375 patent/US10370388B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015507636A5 (https=) | ||
| JP2013545785A5 (https=) | ||
| JP2003531103A5 (https=) | ||
| JP2015504067A5 (https=) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2010536887A5 (https=) | ||
| JP2012526728A5 (https=) | ||
| JP2011201907A5 (https=) | ||
| JP2017523169A5 (https=) | ||
| JP2015505296A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| JP2016503797A5 (https=) | ||
| RU2012138580A (ru) | Производные пиримидина и их применение в лечении респираторных заболеваний, таких как copd | |
| JP2016500661A5 (https=) | ||
| JP2018526367A5 (https=) | ||
| JP2013537203A5 (https=) | ||
| JP2016518434A5 (https=) | ||
| JP2019505529A5 (https=) | ||
| JP2010511626A5 (https=) | ||
| RU2012138579A (ru) | Производные пиримидина и их применение в лечении респираторных заболеваний, таких как copd | |
| JP2013529196A5 (https=) | ||
| JP2015518004A5 (https=) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2021501756A5 (https=) | ||
| JP2015535832A5 (https=) |